升柏控股(02340.HK)擬按“2供1”基準配發供股股份
格隆匯4月11日丨升柏控股(02340.HK)公吿,公司建議按記錄日期合資格股東每持有兩(2)股現有股份獲發一(1)股供股股份的基準,以認購價每股供股股份港幣0.051元(i)發行最多212,425,000股供股股份而籌集最多約港幣10.83百萬元(假設供股項下錄得全數認購及於記錄日期或前已發行現有股份數目並無變動);或(ii)發行最多265,758,333股供股股份而籌集最多約港幣13.55百萬元(假設供股項下錄得全數認購及除於記錄日期或前悉數轉換可換股優先股外,於記錄日期或前已發行現有股份數目並無變動)的所得款項總額。供股僅適用於合資格股東且將不會向不合資格股東(如有)提呈。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.